TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06661694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single 875 mg dose of mevrometostat standard tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single 875 mg dose of mevrometostat standard tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single 875 mg dose of mevrometostat standard tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single 875 mg dose of mevrometostat alternative tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single 875 mg dose of mevrometostat alternative tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single 875 mg dose of mevrometostat alternative tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single 875 mg dose of mevrometostat alternative tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single 875 mg dose of mevrometostat alternative tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single 875 mg dose of mevrometostat alternative tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single 875 mg dose of mevrometostat alternative tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single 875 mg dose of mevrometostat alternative tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Single 875 mg dose of mevrometostat alternative tablet formulation
Study: NCT04710004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Asynchronous distributed multi-electrode stimulation (ADMES) using an implantable neurostimulation device
Description: Participants will receive asynchronous pulses distributed across a multi-electrode array of 16 micro-electrodes and stimulating at low (theta) frequencies.
Study: NCT04818073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New FINGER
Description: New FINGER exoskeleton is a robotic device that can provide assistance and resistance to thumb and finger movement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New FINGER
Description: New FINGER exoskeleton is a robotic device that can provide assistance and resistance to thumb and finger movement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New FINGER
Description: New FINGER exoskeleton is a robotic device that can provide assistance and resistance to thumb and finger movement
Study: NCT05816382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: TAK-861 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: TAK-861 tablets
Study: NCT05490355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Description: RFA involves heating of periarticular nerves using continuous RFA (80-90C for 60-90 seconds) that results in electromodulation and denervation reducing pain. It can be done under fluoroscopy or CT guidance. CT guidance has additional benefit of better localization of the nerves, as opposed to simple bony landmarks used in fluoroscopy, since nerve branching variations are common and will be used in this study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural Steroid Injection
Description: Perineural Steroid Injections involve CT guided injection of Local Anesthetic and Steroid into a nerve root of the spine to provide ongoing pain relief.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineural Steroid Injection
Description: Perineural Steroid Injections involve CT guided injection of Local Anesthetic and Steroid into a nerve root of the spine to provide ongoing pain relief.
Study: NCT05607316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Consistent with previous studies and clinical recommendations, subjects will initiate treatment at metformin 500 mg twice daily and increase to 1000 mg twice daily only after they have tolerated the treatment (details below).~Study Visit 1 (Week 1) - Study Visit 2 (Week 2) Subjects will be directed to take metformin 500 mg twice daily.~Study Visit 2 (Week 2) - Study Visit 5 (Week 24) If initial metformin dose is tolerated, subjects will be directed to increase the dose to 1000 mg by mouth twice daily for the remainder of the study.
Study: NCT05359614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting Elite combined with CoolTone Treatments
Description: Coolsculpting treatment combined with Cooltone treatments for the banana roll region of the buttocks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoolSculpting Elite
Description: Coolsculpting treatment alone for the banana roll region of the buttocks
Study: NCT05793281

Intervention type: OTHER
Intervention: No Drug
Description: Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.
Study: NCT06661694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Single 875 mg dose of mevrometostat alternative tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Single 875 mg dose of mevrometostat alternative tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Single 875 mg dose of mevrometostat alternative tablet formulation
Study: NCT06663436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: altSonflex1-2-3 Dose A
Description: altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: altSonflex1-2-3 Dose B
Description: altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: altSonflex1-2-3 Dose C
Description: altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TYPHIBEV
Description: TYPHIBEV administered intramuscularly on Day 1

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Infanrix hexa administered intramuscularly on Day 169

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MR-VAC
Description: MR-VAC co-administered subcutaneously on Day 1 and Day 169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MR-VAC
Description: MR-VAC co-administered subcutaneously on Day 1 and Day 169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MR-VAC
Description: MR-VAC co-administered subcutaneously on Day 1 and Day 169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MR-VAC
Description: MR-VAC co-administered subcutaneously on Day 1 and Day 169
Study: NCT06657833

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon
Description: Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent
Description: Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent
Study: NCT06539845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outbreak Preparedness Intervention for the Orang Asli
Description: The chosen villages will be given the intervention package, which includes a workshop, simulation exercises, and a card game, in addition to educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This entire package will be delivered once, during the workshop, after they have answered the survey at T0.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Brochures for the Orang Asli
Description: The chosen villages will be given educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This will be given once during the first encounter with the participant, after they have answered the survey at T0.
Study: NCT06424392

Intervention type: OTHER
Intervention: General Health Questionnaire (GHQ-12)
Description: Anxiety and depression self-reported scales for both parents

Intervention type: OTHER
Intervention: State-Trait Anxiety Inventory (STAI-Y)
Description: Anxiety and depression self-reported scales for both parents

Intervention type: OTHER
Intervention: Revised Children's Manifest Anxiety Scale (RCMAS)
Description: Anxiety and depression self-reported scales for children

Intervention type: OTHER
Intervention: World Health Organization Quality of Life (WHOQOL-BREF)
Description: Quality of life self-reported scales for parents

Intervention type: OTHER
Intervention: Parental Educational Competence Self-Evaluation Questionnaire Questionnaire d'Auto-Évaluation de la Compétence Éducative Parentale (QAECEP)
Description: Parental Educational Competence Self-Evaluation self-reported Questionnaire for parents

Intervention type: OTHER
Intervention: Parental interview
Description: The interview will only last about ten minutes and will take place during the first call, if the parents have agreed and are sufficiently available to answer. If the parents are not available, an appointment can be made at a later date
Study: NCT06664827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi PTS Blood Flow Restriction Tourniquet System
Description: In Houston Methodist rehabilitation clinics these devices are used as standard of care for BFR therapy in many post-operative treatments. General guidelines suggest using ranges between 30% - 80% of limb occlusion pressure (LOP). In our previous research efforts involving BFR the investigators have adhered to these guidelines and experienced no adverse events while observing these ranges to be well tolerated by subjects.
Study: NCT05281471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: olvimulogene nanivacirepvec
Description: Olvi-Vec is an engineered oncolytic vaccinia virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum chemotherapy: carboplatin (preferred) or cisplatin
Description: Administered according to local practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum chemotherapy: carboplatin (preferred) or cisplatin
Description: Administered according to local practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Description: Administered according to local practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Description: Administered according to local practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (or biosimilar)
Description: Administered according to local practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (or biosimilar)
Description: Administered according to local practice
Study: NCT06607523

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Inulin, 4g twice daily for 42 days
Study: NCT06606743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Participants will receive a total of 20 in-person sessions of 45 minutes duration. Subjects perform high-speed movements with minimal recovery between movements. Hand weight will be used to increase intensity as training progresses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Velocity Circuit Resistance Training
Description: Participants in this group will perform a total of 20 in-person training sessions using 12 resistance exercises performed in 3 circuits with minimal recovery between exercises.
Study: NCT06609057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Receive Cooking for Your Health in Southern New Mexico intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Ancillary studies
Study: NCT06608693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF stretching
Description: Subjects lay supine on a treatment table, holding one knee to the chest and letting the other leg extend freely toward the floor at the end of the table. This protocol was adapted from previous studies. The hip joint was carefully and gradually lowered towards the floor, with the knee flexing at a 90-degree angle until the individual experienced a mild stretching sensation (Visual analog scale:4-6). Then, the subject performed a sub-maximal voluntary isometric contraction by utilizing the flexor muscles for 20 seconds while resisting the applied force exerted by an examiner through the utilization of a hand-held dynamometer (K-Force Muscle Control). The examiner proceeded to passively manipulate the leg to achieve the desired range of motion (ROM), maintaining it for 20 seconds. This process was repeated six times for each limb. The patient rested for 2 minutes before applying the same technique to the other side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching group
Description: While the patient was lying supine, the hip and knee joints on the non-stretch side were kept in 90⸰ flexion. A sandbag was positioned on the side to be stretched, specifically proximal to the patella, in order to induce a moderate sensation of stretching in the patient. Subsequently, a force was exerted in the direction of hip extension for a duration of 30 seconds. Afterward, the patient was instructed to relax. This process was repeated a total of six times, with a designated 20-second rest period between each repetition. The patient took a two-minute rest before the same technique was applied to the other side. There was no specific order on which side to apply the technique.
Study: NCT06608186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix drug
Description: a drug injection daily sc. from day 5 of stimulation till hCG trigger day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone drug
Description: A drug drospirenone in the form of 1 tablet / d from day 5 of stimulation till hCG trigger day
Study: NCT06607549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine and rituximab (Lonca-R)
Description: Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 4 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).
Study: NCT06498960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CereVasc eShunt System
Description: The eShunt System consists of the following components:~* eShunt Implant~* eShunt Delivery Catheter and Transfer Tool~* eShunt Anchor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VP Shunt
Description: Control arm - VP shunt
Study: NCT06598345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Pet Fish Care
Description: Participants in the Routine Group will be provided specific instructions for coupling the daily and weekly fish care and diabetes care throughout the 12-week intervention They will also be told to monitor BG four times daily, review BG readings with their parent weekly and document the BG checks and weekly reviews on their device's software.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Pet Fish Care
Description: Participants in the Routine Group will be provided specific instructions for coupling the daily and weekly fish care and diabetes care throughout the 12-week intervention They will also be told to monitor BG four times daily, review BG readings with their parent weekly and document the BG checks and weekly reviews on their device's software.
Study: NCT05182411

Intervention type: OTHER
Intervention: assessment
Description: Turkish version of Leg Activity Measure Rivearmead Mobility Index Nottingham Health Profile Functional Independence Measures
Study: NCT05664308

Intervention type: OTHER
Intervention: Clinical follow-up (ECG)
Description: Clinical follow-up with a consultation at the University Hospital at 3, 6, and 12 months, with an ECG at each visit.

Intervention type: OTHER
Intervention: Clinical follow-up (ECG)
Description: Clinical follow-up with a consultation at the University Hospital at 3, 6, and 12 months, with an ECG at each visit.

Intervention type: OTHER
Intervention: Ongoing monitoring
Description: Once operated, patients will be monitored remotely via a computerized data transfer routine anonymized by the WITHINGS software, based on the data from the watch.~It's contractually agreed with WITHINGS that the transmissions will be scheduled and transmitted weekly to the center.
Study: NCT05177146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine (IV)
Description: A sterile form of ketamine hydrochloride will be administered over 40-min IV infusion twice per week on non-consecutive days for four weeks. Dosing schedule is determined based on patient's weight, clinical response and tolerability. First treatment session dose will be calculated based on 0.5 mg/kg. Further dose increase will be determined by the study physician. Dose increase will not exceed 0.8 mg/kg. Patients will be closely monitored by available trained personnel with MD being present on site for the full duration of the 2-h supervision period. Specifically, IV induction will be performed under the direct supervision of anesthesiologist or delegate and psychiatrist. Vital signs will be monitored every 30 minutes during the supervision period. Side effects will be managed by the medical team administering the treatment. If required, appropriate rescue medications will be provided depending on the nature of the adverse event.
Study: NCT06373341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR training for arm and hand rehabilitation
Description: The intervention group will participate in training with a VR-exergame for 4 weeks after inclusion. For this training a Meta Quest VR-headset with a game specifically designed for and with ICU patients that was previously pilot tested for feasibility and safety will be used under supervision of a researcher or caregiver until the patient feels ready to practice alone.
Study: NCT04758195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Description: Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
Study: NCT06598345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Communication
Description: Parents and participants in the Collaborative Communication group will be given recommendations for how to conduct weekly meetings in a collaborative approach based on a modified version of the Minute Meeting protocol.
Study: NCT06600373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Walking meditation
Description: Conduct approximately 10 minutes of mindful walking after the 110-minute regular physical education group class.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical education group class
Description: 120 minutes physical education group class about volleyball.
Study: NCT06587529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Set Me Free Project's (SMFP) READY to Stand (RTS)© Curriculum
Description: Students will receive the Ready to Stand (RTS)© programming over six school days, spread over six weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
Study: NCT06598059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Description: CI632D cochlear implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: CI632D, dexamethasone-eluting cochlear implant
Study: NCT06603571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136
Description: Administered SC
Study: NCT04758195

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive therapy
Description: Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
Study: NCT05254899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: 200mg iv on Day 1 of each 14-day cycle for 3 cycles in induction treatment; 200mg iv on Day 1,15, 29 during RT treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 3000 U/m2 im on Day 2 of each 14-day cycle for 3 cycles in induction treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved site radiotherapy
Description: Involved site radiotherapy according to the ILROG guideline with primary tumor dose of 50-56Gy 14-28 days after inductive therapy